ImmuCell Corporation
ICCCRating Trend
Earnings History
Next report: Nov 12, 2026 · EPS est. $0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $0.20 | $0.05 | $7.2M | $5.4M |
| May 14, 2026 | $0.21 | $0.05 | $10.4M | $5.4M |
| Mar 4, 2026 | $-0.31 | $-0.01 | $7.6M | $5.4M |
| Nov 13, 2025 | $-0.02 | — | $5.5M | — |
| Aug 14, 2025 | $0.06 | — | $6.4M | — |
| May 14, 2025 | $0.16 | — | $8.1M | — |
| Feb 25, 2025 | $0.06 | — | $7.8M | — |
| Nov 13, 2024 | $-0.09 | — | $6.0M | — |
News
Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026.
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
ImmuCell Corporation (NASDAQ: ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $8.64 and traded as high as $10.49. ImmuCell shares last traded at $10.06, with a volume of 11,130 shares traded. Analysts Set New Price Targets A number
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.